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cu.2012.Abstract Three simple stability-indicating methods for the analysis of Zaﬁrlukast (ZAF) in the
presence of its alkaline degradation products were developed and validated as per the International
Conference on Harmonization (ICH) guidelines to evaluate the stability-indicating power of the
proposed methods. The developed high-performance liquid chromatographic technique was
achieved on ZORBAX–ODS (5 lm, 150 · 4.6 mm, i.d.) by isocratic elution with a mixture of aceto-
nitrile/0.05 M phosphate buffer, pH 5.0, (50:50; v/v) as a mobile phase at ﬂow rate of 1.0 mL min1,
followed by UV detection at 240 nm. The method could determine ZAF in the range of 2–40 lg mL
1 with a mean percentage recovery of 99.73 ± 0.903. The proposed HPLC method was utilized to
investigate the kinetics of alkaline degradation of ZAF. First derivative of the ratio spectra (1DD)
method was applied to analyze the drug under investigation without any interference from its deg-
radation product with a linearity range of 4–32 lg mL1 and with a mean percentage recovery of
99.85 ± 0.608. A chemometric method was also developed using the partial least squares (PLS)
model for selective determination of ZAF in the range of 4–40 lg mL1, the mean percentage
recovery was found to be 100.00 ± 0.336.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Zaﬁrlukast (ZAF), chemically [4-(5-cyclopentyloxy-carbonylami-
no-1-methyl-indol-3-ylmethyl)-3-methoxy-n-o-tolylsulfonylbenza-.com
aculty of Pharmacy, Cairo
g by Elsevier
, Cairo University. Production and
07.005mide] is a novel selective peptide leukotriene receptor antagonist,1
used as an antiasthmatic drug in the prophylaxis and treatment of
mild-to-moderate chronic asthma in adults and children.2 ZAF is a
competitive orally administered inhibitor of the cysteinyl
leukotriene LTC4, LTD4 andLTE4 in respiratory tracts.
3 By using
zaﬁrlukast as a single dose, bronchoconstriction caused by foreign
allergens is inhibited and also decreases the bronchial hyper
responsiveness to the inhaled histamine. Bioavailability is reduced
when administrated after a high fat or protein meal. It is highly
bounded to plasma proteins especially albumin (99%). It is
metabolized in the liver by the cytochrome P450 enzyme. Its half
life is about 10 h and the onset of action was seen in 1 h and takeshosting by Elsevier B.V. Open access under CC BY-NC-ND license.
112 A.M. Abou Al Alamein3 h to reach peak plasma concentration. ZAF is eliminatedmainly
through feces (90%) and 10% only in the urine.4,5
Till date there are only few analytical methods reported for
the estimation of ZAF in pharmaceutical preparations and in
biological ﬂuids. These methods include high performance
liquid chromatography,6–10 capillary electrophoresis,11 spec-
trophotometry,7,12 and electrochemical methods.13,14
Nowadays, investigation on the chemical stability and
kinetics of decomposition of drugs is an essential matter to
the quality control of pharmaceuticals and to understand the
degradation pathway of drugs which is important to evaluate
the product’s shelf-life period. Up to now no literature review
is reported for kinetic studies of the degradation process of
ZAF, so the presented work is concerned to investigate the
kinetics of the alkaline degradation process of the cited drug
using the proposed HPLC method.
The aim of the present work is to develop simple, sensitive
and selective stability-indicating methods for the quantitative
determination of Zaﬁrlukast in the presence of its alkaline
degradation product and in pharmaceutical formulations. This
was achieved by developing different techniques including
HPLC, ﬁrst derivative of the ratio spectra and PLS
mathematic methods.
2. Experimental
2.1. Instrumentation
High performance liquid chromatography composed of a
quaternary pump (1200 series, G 1311A) with an ultraviolet
variable wavelength detector, 1200 series (Agilent Technolo-
gies, Waldbronn, Germany) and equipped with a 20-ll injector
loop manual injector (model 7725 I USA), Dual-beam UV–
visible spectrophotometer, (UVProbe 1800 version 2.32
Shimadzu, Kyoto, Japan) with matched 1-cm quartz cells, con-
nected to an IBM compatible personal computer (PC) and a
HP-600 inkjet printer. Bundled, UV-PC personal spectroscopy
software version 3.7, was used to process the absorption and
the derivative spectra. The data were then exported into
MICROSOFT EXCEL program. The chemometric calcula-
tions were performed in Matlab for Windows version 7
Mathworks Inc. 2004. The PLS procedure was taken from
PLS Toolbox 2.1, Eigenvector Research Inc. 2001 created by
B.M. Wise, N.B. Gallagher for use with Matlab.
2.2. Materials and reagents
Pure samples of Zaﬁrlukast were kindly supplied by DELTA
PHARMA S.A.E, Tenth of Ramadan City, A.R.E.
The purity of the samples was found to be 100.43 ±
0.735% (n= 5) according to the reported method.7
Ventair tablets, Batch No. 06093, labeled to contain
20 mg of Zaﬁrlukast per tablet; manufactured by DELTA
PHARMA S.A.E, Tenth of Ramadan City, Egypt.
Acetonitrile and methanol (HiPer Solv, HPLC grade, E.
Merck, Darmstadt, FRG).
All other chemicals were of analytical grade.
2.3. Standard solutions for the drug
Standard stock solutions of ZAF (800 lg mL1) were prepared
by dissolving the pure sample in acetonitrile.For the HPLC-method, a working standard solution
(80 lg mL1) was prepared in the described mobile phase by
10-times dilution of the stock solution. While, other working
standard solutions (80 lg mL1 and 40 lg mL1) were pre-
pared in acetonitrile for the ﬁrst derivative of ratio spectra
method (1DD) and chemometric method, respectively.
2.4. Preparation of the alkali-induced degradation product
Accurately weighed 80 mg of ZAF was dissolved in 20 mL ace-
tonitrile. Subsequently, 25 ml 1 M sodium hydroxide was
added and the solution was heated in a temperature controlled
oven at 100 C for 2.5 h. The solution was concentrated nearly
to dryness under vacuum, cooled to room temperature
(25 C), then quantitatively transferred into a 100-mL mea-
suring ﬂask and the volume was completed with acetonitrile.
Complete alkaline degradation of the studied drug was con-
ﬁrmed by the proposed HPLC method, where no peaks corre-
sponding to intact drug were detected in case of the degraded
samples.
Structural elucidation of the obtained degradation product
was achieved by IR and Mass spectrophotometry.
2.5. Analytical techniques
2.5.1. Solution stability
The solution stability of zaﬁrlukast was evaluated by leaving
the standard solutions (20 lg mL1 in acetonitrile) in tightly
capped volumetric ﬂasks, protected from light on a laboratory
bench and in the refrigerator. The stability of studied com-
pound solutions was checked by the proposed HPLC method.
2.5.2. Calibration curve for HPLC method
A series of standard solutions containing 2–40 lg mL1 ZAF,
were prepared by suitably diluting aliquots of the working
standard solution of ZAF using acetonitrile/water (50:50; v/v).
The chromatographic separation was carried out at ambi-
ent temperature on a ZORBAX–ODS (150 · 4.6 mm, i.d.),
particle size (5 lm), (Agilent Technologies, Waldbronn,
Germany), isocratically at 1.0 mL min1 with a mobile phase
consisting of a mixture of acetonitrile/0.05 M phosphate
buffer, pH 5.0, (50:50; v/v). The mobile phase was ﬁltered
through a 0.45 lmMillipore membrane ﬁlter and was degassed
for 15 min. in an ultrasonic bath prior to use. To reach
equilibrium, the analysis was usually started after the passage
of 50–60 mL of the mobile phase. The eluted analytes were
detected at 240 nm, with a sensitivity of 0.001 AUFS
(Absorbance Unit Full Scale).
Triplicate 20-lL injections were made for each solution and
the peak area ratios of the cited drug to 12 lg mL1 ZAF as an
external standard were plotted against the corresponding
concentrations to obtain the calibration graph.
2.5.3. Calibration curve for ﬁrst derivative of ratio spectra
method (1DD)
Accurately measured volumes of ZAF stock solution (0.5–
4 mL) were transferred separately into 10-mL calibrated ﬂasks,
diluted to volume with acetonitrile/water (50:50; v/v) to reach
the concentration range of 4–32 lg mL1.The zero-order
spectra of ZAF standard solutions were recorded using the
same solvent as a blank and divided by the 8 lg ml1 spectrum
of the completely degraded drug substance. The ﬁrst derivative
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and scaling factor = 10 and the values at a maximum
(232.4 nm) were measured. The calibration curve was con-
structed by relating the peak amplitudes to the corresponding
concentrations and the regression equation was computed.
2.5.4. Training and validation sets for the PLS method
Different 20 mixtures of ZAF and its alkaline degradation
product were prepared by transferring different volumes of
their corresponding standard working solutions (40 lg mL1)
into 10 ml measuring ﬂasks, completing the volume with aceto-
nitrile. Ten samples were used for calibration and the other ten
samples were used as external validation set. The concentra-
tion ranges and the composition of the calibration and valida-
tion samples are given in Table 1.
The absorbances of these solutions were scanned between
200 and 400 nm and were exported to MATLAB 7 for sub-
sequent data manipulation. The suggested model was applied
to predict the concentrations of ZAF in the validation samples.
2.5.5. Laboratory prepared mixtures
Aliquot portions (1–9 mL) of the intact ZAF working solution
(40 lg mL1) were accurately transferred into a series of 10-
mL measuring ﬂasks. Different portions of the alkaline
degradation product (40 lg mL1) were also added to prepare
different mixtures containing 10–90% of the degradates, then
the volume was completed with acetonitrile/water (50:50;
v/v). The samples were analyzed by the proposed HPLC and
1DD methods and the concentrations of the intact drug were
calculated from the corresponding regression equations.
2.5.6. Application to pharmaceutical preparation
Twenty tablets were weighed and ﬁnely powdered. A portion
of the powder equivalent to about 20 mg of ZAF wasTable 1 The concentration of different mixtures of Zaﬁrluk-
ast and degradation product used in the training and validation
sets.
Mixture
numbera
Percentage of
degradation
(%)
Intact ZAF
(lg ml1)
Degraded
Z AFb (lg ml1)
1 0 40 0
2 8.05 36 3.22
3 16.1 32 6.44
4 24.15 28 9.66
5 32.2 24 12.88
6 40.25 20 16.1
7 48.3 16 19.32
8 56.35 12 22.54
9 64.4 8 25.76
10 72.45 4 28.98
11 5.63 37.2 2.25
12 14.5 32.8 5.80
13 22.55 28.8 9.02
14 30.6 24.8 12.24
15 38.65 20.8 15.46
16 41.85 19.2 16.74
17 52 14 20.8
a Mixtures number 1–10 are those used for training set, while
mixtures number 11–17 are those used for validation set.
b Concentrations of degraded samples are calculated on the basis
of 1 M of intact drug that produces 1 M of degradation product.accurately weighed, dissolved and diluted to 50 mL with aceto-
nitrile. The sample solution was ﬁltered. Further dilutions of
the sample solution were carried out with acetonitrile/water
(50:50; v/v) to reach the linearity range speciﬁed for the studied
drug. The general procedures described under the construction
of calibration curve were followed and the concentration of in-
tact ZAF was calculated.
2.5.7. Kinetic studies on the alkaline degradation of ZAF by the
proposed HPLC method
Into a series of 10 test tubes, 2.5 mL of ZAF working solu-
tion 80 lg mL1 was transferred and mixed with 2 mL of
1.0 M sodium hydroxide. The test tubes were allowed to
stand in a thermostatically controlled oven at 100 C and
then were removed from the oven, one by one at 15 min time
intervals up to 180 min. The test tubes were immediately in-
serted into an ice-bath to terminate the degradation reaction
and then were put in another water bath set at room
temperature.
The contents of the test tubes were transferred into 10 mL
volumetric ﬂasks and diluted to volume with acetonitrile/water
(50:50; v/v). The proposed HPLC method was applied for the
determination of the remaining intact ZAF at each time inter-
val from its corresponding regression equation. A plot of log
of the remaining concentration versus time in minutes was then
performed to determine the kinetic order of alkaline degrada-
tion process.
For studying the effect of sodium hydroxide concentration
on the reaction rate, the above procedure was followed using
0.5 and 1.0 M sodium hydroxide at 100 C.
The effect of temperature on the reaction rate was also
studied by following the above procedure using 1 N NaOH
at different temperatures; 40, 60, 80, 90, and 100 C.3. Results and discussion
3.1. Identiﬁcation of the degradation product
Zaﬁrlukast is smoothly hydrolyzed with 1 M sodium hydrox-
ide after 2.5 h at 100 C, through the splitting of the ester
group. The expected major degradation product (DG) is ob-
tained according to the suggested mechanism for the alkaline
degradation process of Zaﬁrlukast,15–18 (Fig. 1). The assign-
ments and structural elucidation of the degradation product,
were conﬁrmed by the IR and mass spectral data. The IR
spectrum (KBr) of DG was characterized by the absorption
frequency of NH2-band as a doublet at 3434.6 cm
1. The mass
spectrum of DG was characterized by the appearance of the
molecular ion peaks at 463 m/z and 465 m/z (M &M+2) which
conﬁrm the molecular weight of the suggested degradation
product.
3.2. Method development and optimization
The quantitative determination of ZAF in the presence of its
alkaline degradation product by conventional zero order spec-
trophotometry is completely hindered due to the strong spec-
tral overlap throughout the wavelength range (Fig. 2).
The suggested methods used to resolve a complex mixture
of such compounds are mainly HPLC, ﬁrst derivative of ratio
spectra and chemometric methods.
Figure 2 Zero-order spectra of pure Zaﬁrlukast (––) and its
degradate (- - -), each of 8 lg ml1.
Figure 3 HPLC chromatogram of intact and degraded Zaﬁrluk-
ast, each of 20 lg ml1.
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Figure 1 Scheme of alkaline degradation of ZAF.
114 A.M. Abou Al Alamein3.2.1. HPLC method
3.2.1.1. System suitability. The developed HPLC method has
been applied for the separation and determination of ZAF in
the presence of its alkaline degradation product. To optimize
the HPLC assay parameters, the mobile phase composition
was studied. A satisfactory separation was obtained with a mo-
bile phase consisting of acetonitrile/0.05 M phosphate buffer,
pH 5.0, (50:50; v/v) at an ambient temperature with a ﬂow rate
of 1.0 mL min1, followed by UV detection at 240 nm. All
peak parameters of resolution efﬁciency were calculated to en-
sure that the system is working correctly during the analysis. In
the proposed system zaﬁrlukast peak was eluted with a resolu-
tion of 20.62, a capacity factor (k) 2.50, tailing factor (T) 1.05,
a relative retention time 5.89 and number of theoretical plates
(N) 5282.19,20
HPLC chromatogram of a mixture of intact and degraded
ZAF sample is shown in Fig. 3, where complete baseline sepa-
ration of ZAF and its degradation product was noticed. The
average retention time for ZAF and DG, were found to be
5.6 ± 0.2 and 1.2 ± 0.3, respectively for 10 replicates.
3.2.1.2. Kinetic investigation. Investigation into the chemical
stability of pharmaceutical products is a matter of growing
concern in many analytical laboratories. This is because sys-
tematic kinetic studies of the decomposition of drugs using sta-
bility testing techniques are essential for the quality control of
such products. In stability studies, drugs co-exist with their
degradation products; thus it is necessary to use an appropri-
ate analytical method to determine one of them in the presence
of the other.21,22
In this work, we report a kinetic investigation of alkaline
degradation of ZAF. Calculations have been based on the
measurement of the concentration of the remaining intact drug
using the previously described HPLC method.
The advantages of using HPLC over spectrometric methods
in the kinetic study are its separation capabilities, identiﬁca-
tion, quantiﬁcation and puriﬁcation of individual components
of the mixture providing higher speciﬁcity, reproducibility and
sensitivity. In addition, HPLC is an automated process thattakes only a few minutes to produce results (6 min in the
present work). The results produced are of high resolution
and are easy to read, and the tests are easily reproduced via
the automated process.
The kinetics of degradation of ZAF was investigated in 1 N
sodium hydroxide to obtain reliable kinetic data. A regular
decrease in the concentration of intact drug with increasing
time intervals was observed. At the selected temperatures
(40–100 C), the alkaline degradation processes followed
pseudo ﬁrst-order kinetics (Fig. 4). From the slopes of the
Figure 4 Pseudo ﬁrst-order plot for the alkaline degradation of
ZAF at various temperatures using the proposed HPLC method.
Figure 5 Arrhenius plot for the alkaline degradation of ZAF
using the proposed HPLC method.
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constant (Kobs) and half-life (t1/2) for alkaline degradation
processes of ZAF (Table 2).
The effect of temperature was studied and Arrhenius plot
(Fig. 5) was obtained by plotting log Kobs values versus 1/T,
which was found to be linear in the temperature range of
40–100 C for alkaline degradation of ZAF. Effect of NaOH
concentration (0.5, 1 N) was studied by plotting log of the
remaining concentration of intact ZAF against time intervals
in minutes. It was found that the reaction rate was increased
by the effect of 1 N NaOH. The results of kinetic data and
regression parameters are calculated and listed in Table 2.
3.2.2. 1DD Spectrophotometric method
As shown from the zero-order spectra (0D) of the drug and its
alkaline degradates (Fig. 2); there is a great overlapping which
makes the direct determination of the drug in the presence of
its degradation product very difﬁcult.
The technique of ﬁrst derivative of the ratio spectra (1DD)
was proposed and applied as a sensitive, rapid and selective
spectrophotometric method for the determination of zaﬁrluk-
ast in the presence of up to 90% of the degradation product,
using a degradate spectrum of 8 lg ml1 as a constant divisor
and ﬁrst derivative of the obtained spectra was done and
measured at a maximum of 232.4 nm (Fig. 6).
Correct choice of the divisor concentration is playing an
important role in the 1DD method, regarding selectivity andTable 2 Kinetic results for the effect of temperature and NaOH co
ZAF.
Temperature (C) Kobs (h1) t1/2 (h)
40 0.051 13.59
60 0.109 6.36
80 0.182 3.81
90 0.274 2.53
100 0.502 1.38
NaOH concentration 0.5 M 0.120 5.78
1 M 0.480 1.44
a n, Number of experimental points included in the linear ﬁt (log conc.sensitivity. Different degradate spectra (4, 8, 16, 32 lg mL1)
were tried as a divisor, it was found that a degradate spectrum
of 8 lg mL1 is the best one which gives highest sensitivity and
lowest peak noise.
3.2.3. Chemometric method
3.2.3.1. Method optimization. A stability indicating method
based on multivariate calibration model namely Partial least
squares (PLS) was investigated for the selective determination
of zaﬁrlukast in the presence of its alkaline degradation prod-
ucts and in pharmaceutical dosage forms.
A calibration set was designed with 10 calibration samples
containing ZAF and DG and another seven samples were used
for validation set in the ranges and concentrations shown in
Table 1.
The UV spectra of the prepared solutions were recorded
over the range 230–330 nm. Wavelengths (200–229 nm) domi-
nated by noise and non informative spectral region after
330 nm are not included. Spectra were digitized each at
1.0 nm interval and the experimental data points were exposed
to MATLAB version 7.0 for calculations. The selection of
the optimum number of factors for the PLS technique was a
very important step before constructing the models because
if the number of factors retained was more than the required,
more noise will be added to the data. On the other hand, if the
number retained was too small meaningful data that could be
necessary for the calibration might be discarded. In this study
the leave one out cross validation method was used23,24 and the
root mean square error of calibration values (RMSEC) ofncentration on the rate of alkaline degradation of 20 lg mL1 of
Regression equation parameters (n= 8)a
Slope ± SD Intercept ± SD Correlation r2
0.052 ± 0.002 1.309 ± 0.253 0.9699
0.110 ± 0.009 1.310 ± 0.366 0.9972
0.183 ± 0.012 1.310 ± 0. 445 0.9982
0.274 ± 0.024 1.2691 ± 0.545 0.9975
0.502 ± 0.005 1.2808 ± 0.679 0.9973
0.002 ± 0.015 1.342 ± 0.701 0.8653
0.008 ± 0.003 1.304 ± 0.255 0.9915
versus time).
Figure 6 1D-ratio spectra of different concentrations (2–
32 lg ml1) of Zaﬁrlukast using a spectrum of 8 lg ml1 of its
degradate as a divisor.
Figure 7 RMSEC plot of the cross validation results of the
training set as a function of the number of principal components
used to construct the PLS calibrations for Zaﬁrlukast.
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able for PLS method (Fig. 7).
3.2.3.2. Validation of PLS- model. To assess the prediction
ability of the suggested PLS- model, it was used to predict
the concentration of ZAF in the presence of up to 52% of
its degradation product in their laboratory prepared mixtures.
The validation of the suggested model was done using
several diagnostic tools. These tools were grouped into two
categories, which were the model diagnostic tools used to
determine the quality of the model and the sample diagnostic
tools used to study the relationship between the samples and
to identify unusual samples. Also, the concentration residuals
were plotted against the actual concentrations for the valida-
tion set samples. This tool was used to determine whether
the model accounted for the concentration variation in the
validation set and it also provides information about how well
the method would predict future samples. The residuals for all
samples appeared to be randomly distributed around zero.
The root mean square error of prediction (RMSEP) was an-
other diagnostic tool for examining the errors in the predicted
concentrations. It indicated both the precision and accuracy ofpredictions as it played the same role of standard deviation in
indicating the spread of the concentration errors. It is found to
be 0.0703. Also the Q2 values of these models were calculated
as 0.9998 which determined the variation in the sample predic-
tion. So long as its value was closer to one, this indicated good
prediction.
3.3. Method validation
3.3.1. Solution stability
The solution stability of zaﬁrlukast was evaluated by the sug-
gested HPLC method, where the studied compound solutions
exhibited no chromatographic changes for 48 h when kept at
room temperature and for 4 days when stored at 5 C, where
the chromatogram plots in all samples showed only one peak
corresponding to pure zaﬁrlukast with no detectable peaks
for degradation products or impurities.
3.3.2. Linearity and range
Calibration curves for the proposed methods were constructed
and evaluated by their correlation coefﬁcients. Linearity of
HPLC method was obtained in the concentration range of
2–40 lg mL1 of ZAF with mean percentage recoveries of
99.73 ± 0.90, (n= 10). While for 1DD method the linearity
was assessed in the range of 4–32 lg mL1 with mean percent-
age recoveries of 99.85 ± 0.61, (n= 7).
In PLS-method, the predicted concentrations of the valida-
tion samples were plotted against the known concentration
values of ZAF in the range of 4–40 lg mL1, this was used
to determine whether the model accounted for the concentra-
tion variation in the validation set. Plots were expected to fall
on a straight line with a slope of one and zero intercept. ZAF
plot was on a straight line with a slope of 0.9979 ± 0.0005, an
intercept of 0.0602 ± 0.0072, and correlation coefﬁcient of
(r) = 0.9998.
The regression equation parameters for all the proposed
methods were computed and given in Table 3 which show a
good linear relationship for the suggested methods as revealed
by the correlation coefﬁcients. Descriptive statistics of the
regression showed low values of the standard deviation of
intercept and slope which revealed high accuracy with mini-
mum deviations and low scattering of the calibration points.
3.3.3. Detection and quantitation limits (sensitivity)
According to ICH recommendations,25 the approach based on
the S.D. of the response and the slope was used for determin-
ing the detection and quantitation limits (LOD, LOQ). The
theoretical values were assessed and given in Table 3.
3.3.4. Precision
Repeatability was evaluated by assaying freshly prepared solu-
tions in triplicate on the same day having concentrations of 8,
12 and 16 lg mL1 of ZAF by the different suggested
methods.
Intermediate precision was evaluated by assaying freshly
prepared solutions of the above mentioned concentrations in
triplicate in three successive days. The recovery% and
RSD% were then calculated (Table 3).
3.3.5. Speciﬁcity
In order to test the validity and applicability of the proposed
methods as stability-indicating ones, recovery studies were
Table 3 Regression and assay validation parameters for determination of pure samples of Zaﬁrlukast by the proposed methods.
Parameter HPLC-method 1DD-method PLS-method
Linearity (lg mL1) 2–40 lg mL1 4–32 lg mL1 4–40 lg mL1
Slope ± SD 0.0716 ± 0.0165 0.0097 ± 0.0044 0.9979 ± 0.0005
Intercept ± SD 0.0314 ± 0.0054 0.006 ± 0.0003 0.0602 ± 0.0062
Correlation coeﬃcient (r) 0.9999 0.9999 0.9998
Mean recovery %±RSD 99.73 ± 0.903 99.85 ± 0.608 100.00 ± 0.336
LODa (lg ml1) 0.460 1.021 1.167
LOQa (lg ml1) 1.397 3.093 3.537
Precision (RSD %)
Repeatabilityb 0.875–0.358–0.775 1.524–0.457–0.885 1.265–0.684–1.205
Intermediate precisionb 1.300–0.268–0.758 1.631–1.531–0.577 1.832–1.740–0.856
Robustness datac
Standard ZAF(10 lg mL1) 100.25 ± 0.322 100.56 ± 0.558 99.95 ± 0.675
Acetonitrile/buﬀer (48:52, v/v) 100.23 ± 0.399
Acetonitrile/buﬀer (52:48, v/v) 100.56 ± 0.402
Flow rate 0.8 mL min1 100.01 ± 0.556
Flow rate 1.2 mL min1 100.15 ± 0.245
Peak amplitude in 1DD method
at 232.2 nm 100.00 ± 0.706
at 232.6 nm 99.99 ± 0.458
PLS: spectra were digitized each at 0.8 nm and 1.2 nm 100.04 ± 0.822
99.90 ± 0.715
a Limits of detection and quantitation are determined via calculations: LOD= (SD of the response/slope) · 3.3. LOQ= (SD of the response/
slope) · 10.
b The intra-day and inter-day relative standard deviations of 8, 12 and 16 lg ml1 ZAF, each of triplicate analysis.
c Mean recovery %±RSD (n= 5).
Table 4 Determination of the studied drugs in the laboratory prepared (L.P.) mixtures with its degradation product and in tablets by
the proposed methods.
Sample HPLC-methoda 1DD-methoda PLS methoda
L.P.-mixtures 100.23 ± 1.103
(n= 5) b
Up to 90% degradation.
100.46 ± 1.166
(n= 5)b
Up to 90% degradation
99.89 ± 1.231
(n= 7)b
Up to 52% degradation
Ventair tablets, Batch No. 06093 99.76 ± 0.644 100.08 ± 0.892 100.38 ± 0.621
a Recovery ± RSD.
b Sets each of 3 replicates.
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of the intact drug and its degradation product. Results in Ta-
ble 4 conﬁrm the validity and speciﬁcity of the proposed
methods.
3.3.6. Application to commercial tablets
The suggested methods were successfully applied for the deter-
mination of ZAF in Ventair tablets. The results shown in Ta-
ble 4 were satisfactory and with good agreement with the
labeled amounts.
3.3.7. Accuracy
The accuracy of the suggested methods was assessed by apply-
ing standard addition technique by spiking different amounts
of pure zaﬁrlukast samples to the previously analyzed tablets
equivalent to 8 lg mL1 of ZAF. The mean recoveries of the
added drug were calculated and illustrated in Table 5. No
interference due to excipients was observed as shown from
the obtained results.3.3.8. Robustness
The robustness of the developed methods was examined by
detecting the effect of small but deliberate variations of some
of the most important procedure parameters such as percent-
age organic strength and ﬂow rate of the mobile phase in the
HPLC method and wavelength of the peak amplitude in
1DD method (232.2 nm and 232.6 nm). In PLS method, spec-
tra of analyzed mixtures were digitized each at 0.8 nm and
1.2 nm.
None of these variables signiﬁcantly affected the assay of
ZAF and the proposed methods could be considered robust
(Table 3).
3.3.9. Statistical comparison to the reported method
Statistical analysis of the results obtained by the suggested
procedures and the reported HPLC method7 was carried out.
Table 6 shows that the calculated t- and F-values were less than
the theoretical ones, indicating no signiﬁcant differences
between the proposed procedures and the reported one.
Table 5 Application of the standard addition technique to the analysis of the studied drug by the proposed methods.
Method HPLC-method 1DD-method PLS method
Pharmaceutical
preparation
Authentic
added
(lg mL1)
Authentic
found
(lg mL1)
Recovery** (%) Authentic
added
(lg ml1)
Authentic
found
(lg mL1)
Recovery** (%) Authentic
added
(lg mL1)
Authentic
found
(lg mL1)
Recovery** (%)
Ventair tablets*
(Batch No. 06093)
8 8.09 101.13 4 3.98 99.50 4 4.05 101.25
12 12.15 101.25 8 7.89 98.63 8 8.06 100.75
16 15.86 99.13 12 12.15 101.25 12 11.85 98.75
24 24.0–13 100.54 16 16.24 101.50 16 15.85 99.06
Mean ± SD 100.51 ± 0.973 100.22 ± 1.384 99.95 ± 1.233
CV 0.968 1.381 1.234
* Equivalent to 8 lg mL1 of ZAF.
** Average of at least 3 experiments.
Table 6 Statistical analysis of the proposed methods and the reported method of Zaﬁrlukast in the pure powder form.
Parameter HPLC method 1DD-method PLS method Reported** method7
Mean 99.73 99.85 99.89 100.43
SD 0.901 0.607 0.336 0.735
N 10 7 7 5
Variance 0.812 0.368 0.113 0.540
Student’s t- 1.386 1.306 0.599
(2.160)* (2.228)* (2.228)*
F 1.504 1.467 2.796
(6.00)* (6.16)* (6.16)*
* Figures in parenthesis are corresponding theoretical t- and F-values at p= 0.05.
** Reported HPLC method is carried out with a Symmetry Shield RP18, 250 · 4.6 mm column. The mobile phase constituted of 0.01 M
potassium dihydrogen phosphate buffer and acetonitrile (30:70, v/v), pH adjusted to 3.5 with ultraviolet detection at 225 nm.
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A simple isocratic HPLC method and newly developed 1DD
and PLS methods are presented as stability indicating methods
for the determination of zaﬁrlukast in the presence of its
alkaline degradation product.
From the previous discussion and results obtained in this
work, we can conclude with 95% of conﬁdence that the three
suggested methods are simple, sensitive, selective and can be
applied for quality control and routine analysis of zaﬁrlukast
in pure form, in the presence of its alkaline degradation prod-
uct and in the available dosage form without any interference
from the excipients. In addition, the suggested HPLC method
has an advantage over the reference one7 of being used to
investigate the kinetics of alkaline degradation process of
zaﬁrlukast in a detailed study.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.bfopcu.
2012.07.005.
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